Korman H J, Peabody J O, Cerny J C, Farah R N, Yao J, Raz A
Department of Urology, Henry Ford Hospital, Detroit, Michigan 48201, USA.
J Urol. 1996 Jan;155(1):347-9.
To determine whether autocrine motility factor receptor (AMFR) is detectable in the urine of patients with transitional cell carcinoma (TCC) of the bladder.
We assayed the urine of 89 patients with bladder pathology and 28 normal controls for AMFR. A monoclonal antibody to AMFR was used.
All patients with muscle-invasive TCC tested positive for AMFR. Autocrine motility factor receptor was detectable for 80% of superficial tumors, with a correlation between AMFR and tumor grade. Seventy-five percent of control urines tested negative.
Autocrine motility factor receptor is detectable in the urine of patients with TCC. Long-term follow-up and refinements in the assay should define the marker's utility for detection and prognosis.
确定膀胱移行细胞癌（TCC）患者尿液中是否可检测到自分泌运动因子受体（AMFR）。
我们检测了89例膀胱病变患者及28例正常对照者尿液中的AMFR。使用了针对AMFR的单克隆抗体。
所有肌层浸润性TCC患者的AMFR检测均呈阳性。80%的浅表肿瘤可检测到自分泌运动因子受体，且AMFR与肿瘤分级相关。75%的对照尿液检测为阴性。
TCC患者尿液中可检测到自分泌运动因子受体。长期随访及检测方法的改进应能明确该标志物在检测及预后方面的效用。
